# Study of OBT076 Associated or Not in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck

> **NCT05930951** · PHASE1 · TERMINATED · sponsor: **Groupe Oncologie Radiotherapie Tete et Cou** · enrollment: 19 (actual)

## Conditions studied

- Adenoid Cystic Carcinoma of the Head and Neck

## Interventions

- **DRUG:** OBT076
- **DRUG:** Balstilimab

## Key facts

- **NCT ID:** NCT05930951
- **Lead sponsor:** Groupe Oncologie Radiotherapie Tete et Cou
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-29
- **Primary completion:** 2024-10-09
- **Final completion:** 2024-10-09
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** toxicity
- **Last updated:** 2025-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05930951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05930951, "Study of OBT076 Associated or Not in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05930951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*